Lysophosphatidic acid disrupts junctional integrity and epithelial cohesion in ovarian cancer cells

Journal of Oncology

Volumn , Issue , 2012, Pages

  Liu, Yueying ^a   Burkhalter, Rebecca ^a,b   Symowicz, Jaime ^c   Chaffin, Kim ^d   Ellerbroek, Shawn ^d   Stack, M Sharon ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d WARTBURG COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; LYSOPHOSPHATIDIC ACID; UVOMORULIN;

ARTICLE; CELL ADHESION; CELL JUNCTION; CONTROLLED STUDY; EPITHELIUM CELL; OVARY CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INDUCTION;

EID: 84861024878     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/501492     Document Type: Article

References (36)

1. Altekruse S. F., Krapcho K. C. L., Neyman M., Cancer of the ovarySEER stat fact sheets SEER Cancer Statistics Review 19752007 2010 Bethesda, Md, USA National Cancer Institute
2. Hudson L. G., Zeineldin R., Stack M. S., Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression Clinical and Experimental Metastasis 2008 25 6 643 655
3. Barbolina M. V., Moss N. M., Westfall S. D., Fishman D. A., Stack M. S., Microenvironmental regulation of ovarian cancer metastasis Ovarian Cancer 2009 New York, NY, USA Springer
4. Scully R. E., Clement P. B., Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube and Broad Ligament 1998 Washington, DC, USA Armed Forces Institute of Pathology Atlas of Tumor Pathology
5. Fang X., Schummer M., Mao M., Yu S., Tabassam F. H., Swaby R., Hasegawa Y., Tanyi J. L., LaPushin R., Eder A., Jaffe R., Erickson J., Mills G. B., Lysophosphatidic a (Pubitemid 34634137)
6. Westermann A. M., Havik E., Postma F. R., Beijnen J. H., Dalesio O., Moolenaar W. H., Rodenhuis S., Malignant effusions contain lysophosphatidic acid (LPA)-like activity Annals of Oncology 1998 9 4 437 442 (Pubitemid 28273038)
7. Xu Y., Gaudette D. C., Boynton J. D., Frankel A., Fang X. J., Sharma A., Hurteau J., Casey G., Goodbody A., Mellors A., Holub B. J., Mills G. B., Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients Clinical Cancer Research 1995 1 10 1223 1232
8. Xu Y., Shen Z., Wiper D. W., Wu M., Morton R. E., Elson P., Kennedy A. W., Belinson J., Markman M., Casey G., Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers Journal of the American Medical Association 1998 280 8 719 723 (Pubitemid 28405297)
9. Baker D. L., Morrison P., Miller B., Riley C. A., Tolley B., Westerman A. M., Bonfrer J. M. G., Bais E., Moolenaar W. H., Tigyi G., Plasma lysophosphatidic acid concentration and ovarian cancer Journal of the American Medical Association 2002 287 23 3081 3082 (Pubitemid 34633980)
10. Sutphen R., Xu Y., Wilbanks G. D., Fiorica J., Grendys E. C., LaPolla J. P., Arango H., Hoffman M. S., Martino M., Wakeley K., Griffin D., Blanco R. W., Cantor A. B., Xiao Y. J., Krischer J. P., Lysophospholipids are potential biomarkers of ovarian cancer Cancer Epidemiology Biomarkers and Prevention 2004 13 7 1185 1191 (Pubitemid 38917907)
11. Li H., Ye X., Mahanivong C., Bian D., Chun J., Huang S., Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells Journal of Biological Chemistry 2005 280 11 10564 10571 (Pubitemid 40395917)
12. Fishman D. A., Liu Y., Ellerbroek S. M., Stack M. S., Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells Cancer Research 2001 61 7 3194 3199 (Pubitemid 32691975)
13. Jourquin J., Yang N., Kam Y., Guess C., Quaranta V., Dispersal of epithelial cancer cell colonies by lysophosphatidic acid (LPA) Journal of Cellular Physiology 2006 206 2 337 346 (Pubitemid 43062801)
14. Symowicz J., Adley B. P., Woo M. M. M., Auersperg N., Hudson L. G., Stack M. S., Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells Cancer Research 2005 65 6 2234 2242 (Pubitemid 40490132)
15. Fang X., Gaudette D., Furui T., Mao M., Estrella V., Eder A., Pustilnik T., Sasagawa T., Lapushin R., Yu S., Jaffe R. B., Wiener J. R., Erickson J. R., Mills G. B., Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer Annals of the New York Academy of Sciences 2000 905 188 208 (Pubitemid 30255418)
16. Do T. V., Symowicz J. C., Berman D. M., Liotta L. A., Petricoin E. F., Stack M. S., Fishman D. A., Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells Molecular Cancer Research 2007 5 2 121 131 (Pubitemid 46423993)
17. Estrella V. C., Eder A. M., Liu S., Pustilnik T. B., Tabassam F. H., Claret F. X., Gallick G. E., Mills G. B., Wiener J. R., Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway International Journal of Oncology 2007 31 2 441 449
18. Chambers S. K., Gertz R. E. Jr., Ivins C. M., Kacinski B. M., The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer Cancer 1995 75 7 1627 1633
19. Hu Y.-L., Tee M.-K., Goetzl E. J., Auersperg N., Mills G. B., Ferrara N., Jaffe R. B., Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells Journal of the National Cancer Institute 2001 93 10 762 768 (Pubitemid 32514799)
20. Pustilnik T. B., Estrella V., Wiener J. R., Mao M., Eder A., Watt M. A. V., Bast R. C., Mills G. B., Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells Clinical Cancer Research 1999 5 11 3704 3710
21. Ren J., Xiao Y. J., Singh L. S., Zhao X., Zhao Z., Feng L., Rose T. M., Prestwich G. D., Xu Y., Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells Cancer Research 2006 66 6 3006 3014
22. Benitah S. A., Valeron P. F., Rui H., Lacal J. C., STAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoA Molecular Biology of the Cell 2003 14 1 40 53 (Pubitemid 36106018)
23. Covington M. D., Burghardt R. C., Parrish A. R., Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14) American Journal of Physiology 2006 290 1 F43 F51
24. Cowden-Dahl K. D., Symowicz J., Ning Y., Gutierrez E., Fishman D. A., Adley B. P., Stack M. S., Hudson L. G., Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells Cancer Research 2008 68 12 4606 4613
25. Lochter A., Galosy S., Muschler J., Freedman N., Werb Z., Bissell M. J., Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells Journal of Cell Biology 1997 139 7 1861 1872 (Pubitemid 28079248)
26. No V., Fingleton B., Jacobs K., Crawford H. C., Vermeulen S., Steelant W., Bruyneel E., Matrisian L. M., Mareel M., Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1 Journal of Cell Science 2001 114, part 1 111 118 (Pubitemid 32120080)
27. Ohta H., Sato K., Murata N., Damirin A., Malchinkhuu E., Kon J., Kimura T., Tobo M., Yamazaki Y., Watanabe T., Yagi M., Sato M., Suzuki R., Murooka H., Sakai T., Nishitoba T., Im D. S., Nochi H., Tamoto K., Tomura H., Okajima F., Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors Molecular Pharmacology 2003 64 4 994 1005 (Pubitemid 37153068)
28. Symowicz J., Adley B. P., Gleason K. J., Johnson J. J., Ghosh S., Fishman D. A., Hudson L. G., Stack M. S., Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells Cancer Research 2007 67 5 2030 2039 (Pubitemid 46424220)
29. Jiang R., Shi Z., Johnson J. J., Liu Y., Stack M. S., Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma Journal of Biological Chemistry 2011 286 11 9127 9135
30. Gil O. D., Lee C., Ariztia E. V., Wang F. Q., Smith P. J., Hope J. M., Fishman D. A., Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner Gynecologic Oncology 2008 108 2 361 369
31. Du J., Sun C., Hu Z., Yang Y., Zhu Y., Zheng D., Gu L., Lu X., Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3k/PAK1/ERK signaling Plos ONE 2010 5 12
32. Ahmed N., Thompson E. W., Quinn M. A., Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm Journal of Cellular Physiology 2007 213 3 581 588 (Pubitemid 350058249)
33. Sawada K., Mitra A. K., Radjabi A. R., Bhaskar V., Kistner E. O., Tretiakova M., Jagadeeswaran S., Montag A., Becker A., Kenny H. A., Peter M. E., Ramakrishnan V., Yamada S. D., Lengyel E., Loss of E-cadherin promotes ovarian cancer metastasis via 5-integrin, which is a therapeutic target Cancer Research 2008 68 7 2329 2339 (Pubitemid 351521807)
34. Katayama M., Hirai S., Kamihagi K., Nakagawa K., Yasumoto M., Kato I., Soluble E-cadherin fragments increased in circulation of cancer patients British Journal of Cancer 1994 69 3 580 585 (Pubitemid 24076484)
35. Gadducci A., Ferdeghini M., Cosio S., Annicchiarico C., Ciampi B., Bianchi R., Genazzani A. R., Preoperative serum E-cadherin assay in patients with ovarian carcinoma Anticancer Research 1999 19 1 B 769 772 (Pubitemid 29168330)
36. Sundfeldt K., Ivarsson K., Rask K., Haeger M., Hedin L., Brnnstrm M., Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts Anticancer Research 2001 21 1 A 65 70 (Pubitemid 32267626)